Table 3. Association between PITX1 genetic polymorphism and colorectal cancer risk by anatomical sites.
| All | Colorectal cancer | Colon cancer | Rectal cancer | ||||
|---|---|---|---|---|---|---|---|
| Control (%) | Case (%) | OR (95% CI)a | Case (%) | OR (95% CI)a | Case (%) | OR (95% CI)a | |
| Codominant model | |||||||
| CC | 673 (50.6) | 294 (42.8) | 1.00 | 146 (41.8) | 1.00 | 146 (44.4) | 1.00 |
| AC | 548 (41.2) | 321 (46.7) | 1.43 (1.15–1.76) | 166 (47.6) | 1.47 (1.12–1.92) | 149 (45.3) | 1.34 (1.01–1.77) |
| AA | 110 (8.3) | 72 (10.5) | 1.67 (1.16–2.39) | 37 (10.6) | 1.71 (1.08–2.70) | 34 (10.3) | 1.66 (1.03–2.68) |
| Dominant model | |||||||
| CC | 673 (50.5) | 294 (42.7) | 1.00 | 146 (41.8) | 1.00 | 146 (44.4) | 1.00 |
| AC/AA | 658 (49.4) | 393 (57.2) | 1.46 (1.18–1.80) | 203 (58.2) | 1.50 (1.16–1.95) | 183 (55.6) | 1.39 (1.06–1.82) |
| Recessive model | |||||||
| CC/AC | 1221 (91.7) | 615 (89.5) | 1.00 | 312 (89.4) | 1.00 | 295 (89.7) | 1.00 |
| AA | 110 (8.3) | 72 (10.5) | 1.43 (0.99–2.07) | 37 (10.6) | 1.41 (0.92–2.19) | 34 (10.3) | 1.44 (0.92–2.28) |
| Male | |||||||
| Codominant model | |||||||
| CC | 474 (52.1) | 206 (43.9) | 1.00 | 99 (43.2) | 1.00 | 106 (44.7) | 1.00 |
| AC | 361 (40.0) | 218 (46.5) | 1.40 (1.06–1.84) | 108 (47.2) | 1.44 (1.03–2.01) | 108 (45.6) | 1.35 (0.96–1.89) |
| AA | 75 (8.2) | 45 (9.6) | 1.60 (0.99–2.59) | 22 (9.6) | 1.61 (0.90–2.86) | 23 (9.7) | 1.61 (0.89–2.88) |
| Dominant model | |||||||
| CC | 474 (52.1) | 206 (43.9) | 1.00 | 99 (43.2) | 1.00 | 106 (44.7) | 1.00 |
| AC/AA | 436 (47.9) | 263 (56.1) | 1.43 (1.10–1.86) | 130 (56.8) | 1.47 (1.07–2.02) | 131 (55.3) | 1.39 (1.01–1.92) |
| Recessive model | |||||||
| CC/AC | 835 (91.8) | 424 (90.4) | 1.00 | 207 (90.4) | 1.00 | 214 (90.3) | 1.00 |
| AA | 75 (8.2) | 45 (9.6) | 1.36 (0.86–2.16) | 22 (9.6) | 1.35 (0.78–2.34) | 23 (9.7) | 1.40 (0.80–2.44) |
| Female | |||||||
| Codominant model | |||||||
| CC | 199 (47.3) | 88 (40.4) | 1.00 | 47 (39.2) | 1.00 | 40 (43.5) | 1.00 |
| AC | 187 (44.4) | 103 (47.3) | 1.44 (0.96–2.17) | 58 (48.3) | 1.54 (0.94–2.50) | 41 (44.6) | 1.30 (0.77–2.20) |
| AA | 35 (8.3) | 27 (12.4) | 1.88 (0.97–3.65) | 15 (12.5) | 1.86 (0.85–4.04) | 11 (12.0) | 1.79 (0.77–4.14) |
| Dominant model | |||||||
| CC | 199 (47.3) | 88 (40.4) | 1.00 | 47 (39.2) | 1.00 | 40 (43.5) | 1.00 |
| AC/AA | 222 (52.7) | 130 (59.6) | 1.51 (1.02–2.24) | 73 (60.8) | 1.59 (1.00–2.53) | 52 (56.5) | 1.38 (0.83–2.27) |
| Recessive model | |||||||
| CC/AC | 386 (91.7) | 191 (87.6) | 1.00 | 105 (87.5) | 1.00 | 81 (88.0) | 1.00 |
| AA | 35 (8.3) | 27 (12.4) | 1.56 (0.83–2.90) | 15 (12.5) | 1.48 (0.72–3.08) | 11 (12.0) | 1.57 (0.71–3.47) |
aAdjusted for age, gender, education, regular exercise, alcohol, family history of CRC, total energy intake.